Literature DB >> 8339264

Elevated levels of transforming growth factor alpha and epidermal growth factor receptor messenger RNA are early markers of carcinogenesis in head and neck cancer.

J R Grandis1, D J Tweardy.   

Abstract

The squamous mucosa of patients who develop head and neck cancer is "condemned" or predisposed to disregulated growth as reflected by the high incidence of synchronous and metachronous primary tumors. We hypothesized that transformed and nontransformed mucosa from head and neck cancer patients would produce increased levels of transforming growth factor alpha (TGF-alpha) and its cell surface receptor, the epidermal growth factor receptor (EGFR), thereby contributing to this predisposition. Using molecular biological techniques, we examined the incidence and mechanism of TGF-alpha and EGFR overproduction in tumors and histologically normal mucosa excised from patients with squamous cell carcinoma of the head and neck (SCCHN) to test this hypothetical mechanism of field cancerization. Northern blot hybridization was used to evaluate the frequency of increased TGF-alpha and EGFR mRNA production in tissue excised from 24 patients with SCCHN and 10 cell lines compared with 7 control patients without cancer or a history of alcohol and tobacco use. Southern blot hybridization was used to examine for gene amplification. In patients with SCCHN, TGF-alpha mRNA was elevated by a mean of 5-fold in 95% of histologically "normal" mucosa samples (P = 0.001) and by a mean of 5-fold in 87.5% of tumors (P = 0.0001) while EGFR mRNA was elevated by a mean of 29-fold in 91% of histologically normal mucosa specimens (P = 0.0005) and by a mean of 69-fold in 92% of tumors (P = 0.0005), compared with mRNA levels in control normal mucosa. In 10 SCCHN cell lines, TGF-alpha mRNA was increased by a mean of 16-fold and EGFR mRNA levels were increased by a mean of 77-fold. Increased production of TGF-alpha and EGFR mRNA in the histologically normal mucosa of patients at risk for a primary or secondary head and neck cancer may serve both as a marker for malignant transformation and as a target for preventive therapies.

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 8339264

Source DB:  PubMed          Journal:  Cancer Res        ISSN: 0008-5472            Impact factor:   12.701


  257 in total

Review 1.  Chemopreventive potential of natural compounds in head and neck cancer.

Authors:  Mohammad Aminur Rahman; A R M Ruhul Amin; Dong M Shin
Journal:  Nutr Cancer       Date:  2010       Impact factor: 2.900

2.  Poly-L-arginine and dextran sulfate-based nanocomplex for epidermal growth factor receptor (EGFR) siRNA delivery: its application for head and neck cancer treatment.

Authors:  Hyun-Jong Cho; Saeho Chong; Suk-Jae Chung; Chang-Koo Shim; Dae-Duk Kim
Journal:  Pharm Res       Date:  2011-12-15       Impact factor: 4.200

3.  Quantitative proteomics analysis reveals molecular networks regulated by epidermal growth factor receptor level in head and neck cancer.

Authors:  Wei Yang; Quan Cai; Vivian W Y Lui; Patrick A Everley; Jayoung Kim; Neil Bhola; Kelly M Quesnelle; Bruce R Zetter; Hanno Steen; Michael R Freeman; Jennifer R Grandis
Journal:  J Proteome Res       Date:  2010-06-04       Impact factor: 4.466

4.  Tautomerism in drug discovery.

Authors:  Alan R Katritzky; C Dennis Hall; Bahaa El-Dien M El-Gendy; Bogdan Draghici
Journal:  J Comput Aided Mol Des       Date:  2010-05-20       Impact factor: 3.686

5.  p120-catenin suppresses proliferation and tumor growth of oral squamous cell carcinoma via inhibiting nuclear phospholipase C-γ1 signaling.

Authors:  Lusha Li; Shangli Ji; Chandrama Shrestha; Yi Jiang; Liyan Liao; Feng Xu; Zhenming Liu; Daniel D Bikle; Zhongjian Xie
Journal:  J Cell Physiol       Date:  2020-04-30       Impact factor: 6.384

Review 6.  EGFR-targeted therapies in the post-genomic era.

Authors:  Mary Jue Xu; Daniel E Johnson; Jennifer R Grandis
Journal:  Cancer Metastasis Rev       Date:  2017-09       Impact factor: 9.264

7.  A phase II study of temsirolimus and erlotinib in patients with recurrent and/or metastatic, platinum-refractory head and neck squamous cell carcinoma.

Authors:  Julie E Bauman; Hugo Arias-Pulido; Sang-Joon Lee; M Houman Fekrazad; Hiroyuki Ozawa; Elana Fertig; Jason Howard; Justin Bishop; Hao Wang; Garth T Olson; Michael J Spafford; Dennie V Jones; Christine H Chung
Journal:  Oral Oncol       Date:  2013-02-04       Impact factor: 5.337

Review 8.  Current role of EGF receptor monoclonal antibodies and tyrosine kinase inhibitors in the management of head and neck squamous cell carcinoma.

Authors:  Ana Markovic; Christine H Chung
Journal:  Expert Rev Anticancer Ther       Date:  2012-09       Impact factor: 4.512

9.  Multivalent Binding and Biomimetic Cell Rolling Improves the Sensitivity and Specificity of Circulating Tumor Cell Capture.

Authors:  Ja Hye Myung; Michael J Eblan; Joseph M Caster; Sin-Jung Park; Michael J Poellmann; Kyle Wang; Kevin A Tam; Seth M Miller; Colette Shen; Ronald C Chen; Tian Zhang; Joel E Tepper; Bhishamjit S Chera; Andrew Z Wang; Seungpyo Hong
Journal:  Clin Cancer Res       Date:  2018-03-15       Impact factor: 12.531

Review 10.  Molecular pathogenesis of head and neck squamous cell carcinoma.

Authors:  David Hardisson
Journal:  Eur Arch Otorhinolaryngol       Date:  2003-05-08       Impact factor: 2.503

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.